AAS
TGTX icon

Ameritas Advisory Services’s TG Therapeutics TGTX Stock Holding History

Ameritas Advisory Services’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-700
Closed -$25.3K – 1992
2025
Q3 		$25.3K Hold
700
– – ﹤0.01% 1359
2025
Q2 		$25.2K Buy
+700
New +$26.1K ﹤0.01% 1641
2023
Q2 		– Sell
-1,125
Closed -$25.5K – 2331
2023
Q1 		$25.5K Buy
+1,125
New +$17.1K ﹤0.01% 1535

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Ameritas Advisory Services's TGTX Position: Q4 2025 in Review

Ameritas Advisory Services sold out of TG Therapeutics (TGTX) in Q4 2025, closing a stake of 700 shares — an estimated $25.3K sold.

Ameritas Advisory Services first reported a position in TGTX in Q1 2023 and held it in 3 quarters. The position peaked at $25.5K in Q1 2023. 351 funds tracked by Wall St. Rank hold TGTX as of Q4 2025.

  • Ameritas Advisory Services reported no remaining TG Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Ameritas Advisory Services sold 700 TG Therapeutics shares in Q4 2025, an estimated $25.3K.
  • Ameritas Advisory Services first reported a position in TG Therapeutics in Q1 2023 and held it in 3 quarters.
  • Ameritas Advisory Services's TG Therapeutics position peaked at $25.5K in Q1 2023.
  • 351 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2025.

Based on Ameritas Advisory Services's 13F filing for Q4 2025, filed 4 Feb 2026.